Multi-Target Pharmacotherapy and Network Pharmacology for CBS/PSP

📖 Wiki Page

therapeutic2992 wordssynced 2026-04-02

Multi-Target Pharmacotherapy and Network Pharmacology for CBS/PSP

Overview

...

Multi-Target Pharmacotherapy and Network Pharmacology for CBS/PSP

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Multi-Target Pharmacotherapy and Network Pharmacology for CBS/PSP</th>
</tr>
<tr>
<td class="label">Drug Class</td>
<td>Primary Target</td>
</tr>
<tr>
<td class="label">[Anti-tau antibodies](/therapeutics/tau-targeted-therapeutics) (E2814, bepranemab)</td>
<td>Extracellular/intracellular tau</td>
</tr>
<tr>
<td class="label">[GLP-1 receptor agonists](/therapeutics/glp1-receptor-agonists) (lixisenatide, semaglutide)</td>
<td>GLP-1R signaling</td>
</tr>
<tr>
<td class="label">[CSF1R inhibitors](/therapeutics/csf1r-inhibitors-neurodegeneration) (PLX5622, pexidartinib)</td>
<td>Microglial proliferation</td>
</tr>
<tr>
<td class="label">[TREM2 agonists](/therapeutics/trem2-therapeutics) (AL002, DNL311)</td>
<td>TREM2 signaling</td>
</tr>
<tr>
<td class="label">[CoQ10](/therapeutics/coenzyme-q10-neurodegeneration)</td>
<td>Mitochondrial complex I</td>
</tr>
<tr>
<td class="label">[Urolithin A](/therapeutics/urolithin-a-mitophagy)</td>
<td>Mitophagy induction</td>
</tr>
<tr>
<td class="label">[NRF2 activators](/therapeutics/nrf2-activators-neurodegeneration) (sulforaphane, oltipraz)</td>
<td>NRF2 transcription</td>
</tr>
<tr>
<td class="label">[Rapamycin](/therapeutics/rapamycin-mtor-inhibition-neurodegeneration)</td>
<td>mTOR pathway</td>
</tr>
<tr>
<td class="label">[Trehalose](/therapeutics/trehalose-neurodegeneration)</td>
<td>Autophagy induction</td>
</tr>
<tr>
<td class="label">Data Type</td>
<td>Source</td>
</tr>
<tr>
<td class="label">Whole genome sequencing</td>
<td>Blood</td>
</tr>
<tr>
<td class="label">Transcriptomics (CSF/blood)</td>
<td>CSF cells, PBMCs</td>
</tr>
<tr>
<td class="label">Proteomics (CSF/plasma)</td>
<td>Lumbar puncture</td>
</tr>
<tr>
<td class="label">Metabolomics</td>
<td>Blood, CSF</td>
</tr>
<tr>
<td class="label">iPSC neurons</td>
<td>Skin/blood reprogramming</td>
</tr>
<tr>
<td class="label">Priority</td>
<td>Candidate</td>
</tr>
<tr>
<td class="label">High</td>
<td>[Ambroxol](/therapeutics/ambroxol-parkinsons) (GCase activator)</td>
</tr>
<tr>
<td class="label">High</td>
<td>[Brotizolam](/therapeutics/brotizolam-neurodegeneration) (GABA-A)</td>
</tr>
<tr>
<td class="label">Medium</td>
<td>[Siguin](/therapeutics/small-molecule-drugs) (kinase inhibitor)</td>
</tr>
<tr>
<td class="label">Medium</td>
<td>[Dapansutrile](/therapeutics/dapansutrile-parkinsons) (NLRP3 inhibitor)</td>
</tr>
<tr>
<td class="label">Medium</td>
<td>[Buntanetap](/therapeutics/buntanetap) (translation inhibitor)</td>
</tr>
<tr>
<td class="label">Component</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">[Lixisenatide](/therapeutics/lixisenatide)</td>
<td>20 μg daily</td>
</tr>
<tr>
<td class="label">[CoQ10](/therapeutics/coenzyme-q10-neurodegeneration)</td>
<td>300mg BID</td>
</tr>
<tr>
<td class="label">[Sulforaphane](/therapeutics/sulforaphane-nrf2-activator)</td>
<td>100mg daily</td>
</tr>
<tr>
<td class="label">Phase</td>
<td>Duration</td>
</tr>
<tr>
<td class="label">1. Stabilization</td>
<td>Months 1-3</td>
</tr>
<tr>
<td class="label">2. Enhancement</td>
<td>Months 4-9</td>
</tr>
<tr>
<td class="label">3. Intensive</td>
<td>Months 10-18</td>
</tr>
<tr>
<td class="label">4. Maintenance</td>
<td>Ongoing</td>
</tr>
<tr>
<td class="label">Drug A</td>
<td>Drug B</td>
</tr>
<tr>
<td class="label">Levodopa</td>
<td>[Antipsychotics](/therapeutics/antipsychotics-neurodegeneration) (except clozapine/quetiapine)</td>
</tr>
<tr>
<td class="label">Levodopa</td>
<td>[Entacapone](/therapeutics/entacapone) (COMT inhibitor)</td>
</tr>
<tr>
<td class="label">Levodopa</td>
<td>[Cholinesterase inhibitors](/therapeutics/cholinesterase-inhibitors-comprehensive) (donepezil, rivastigmine)</td>
</tr>
<tr>
<td class="label">Rasagiline</td>
<td>[Lithium](/therapeutics/lithium-tauopathy)</td>
</tr>
<tr>
<td class="label">Rasagiline</td>
<td>Tramadol, meperidine, dextromethorphan</td>
</tr>
<tr>
<td class="label">Rasagiline</td>
<td>[SSRI antidepressants](/therapeutics/ssri-antidepressants) (fluoxetine, sertraline)</td>
</tr>
<tr>
<td class="label">Rasagiline</td>
<td>[Dopamine agonists](/therapeutics/dopamine-agonists)</td>
</tr>
<tr>
<td class="label">Rasagiline</td>
<td>[CoQ10](/therapeutics/coenzyme-q10-neurodegeneration)</td>
</tr>
<tr>
<td class="label">Rasagiline</td>
<td>[Vitamin B6](/therapeutics/supplements-guide-cbs-psp) (high dose >50mg/day)</td>
</tr>
<tr>
<td class="label">Rasagiline</td>
<td>[Tyramine-rich foods](/therapeutics/rasagiline)</td>
</tr>
<tr>
<td class="label">Timepoint</td>
<td>Assessment</td>
</tr>
<tr>
<td class="label">Baseline</td>
<td>CBC, CMP, lipid panel, NfL, p-tau217, ECG, blood pressure</td>
</tr>
<tr>
<td class="label">Week 1-2</td>
<td>Side effects, blood pressure, symptoms</td>
</tr>
<tr>
<td class="label">Week 4</td>
<td>Labs (CBC, CMP), symptom assessment</td>
</tr>
<tr>
<td class="label">Monthly</td>
<td>Blood pressure, weight, symptom tracking</td>
</tr>
<tr>
<td class="label">Quarterly</td>
<td>Biomarker labs (NfL, p-tau217), imaging if available</td>
</tr>
<tr>
<td class="label">Annually</td>
<td>Full neurological assessment, comprehensive labs</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Score</td>
</tr>
<tr>
<td class="label">Scientific Rationale</td>
<td>9/10</td>
</tr>
<tr>
<td class="label">Clinical Readiness</td>
<td>7/10</td>
</tr>
<tr>
<td class="label">Evidence Level</td>
<td>6/10</td>
</tr>
<tr>
<td class="label">Safety Profile</td>
<td>7/10</td>
</tr>
<tr>
<td class="label">Patient Accessibility</td>
<td>7/10</td>
</tr>
<tr>
<td class="label">Biomarker Monitoring</td>
<td>7/10</td>
</tr>
<tr>
<td class="label">Total</td>
<td>43/60</td>
</tr>
</table>

Corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP) are 4R-tauopathies characterized by multiple concurrent pathological mechanisms: tau aggregation, neuroinflammation, mitochondrial dysfunction, oxidative stress, and synaptic loss. Single-target therapies have demonstrated limited efficacy in these conditions, motivating a network pharmacology approach that targets multiple nodes in the disease network simultaneously[@huang2022].

This page covers the network pharmacology framework for CBS/PSP, evidence-based synergistic drug pairs, computational drug repurposing pipelines, sequential versus simultaneous targeting strategies, safety and interaction matrices, and detailed guidance for patients already on [levodopa](/therapeutics/levodopa) and [rasagiline](/therapeutics/rasagiline).

Network Pharmacology Framework

The CBS/PSP Pathological Network

CBS/PSP can be modeled as an interconnected network where pathological nodes influence each other bidirectionally. Tau pathology drives neuroinflammation, which in turn accelerates tau phosphorylation and spreading. Mitochondrial dysfunction promotes oxidative stress, which exacerbates protein aggregation. This interconnectedness means that targeting a single node rarely produces sufficient disease modification[@cavalla2024].

Mermaid diagram (expand to render)

Multi-Target Drug Classes for CBS/PSP

Network Propagation and Therapeutic Leverage

Network pharmacology identifies high-leverage intervention points where modulating one node can propagate benefits across multiple pathways[@zhang2022]. In CBS/PSP, key leverage points include:

Microglial modulation — [CSF1R inhibitors](/therapeutics/csf1r-inhibitors-neurodegeneration) and [TREM2 agonists](/therapeutics/trem2-therapeutics) reduce neuroinflammation while potentially enhancing tau clearance through improved microglial function[@yun2024]

NRF2 activation — [Sulforaphane](/therapeutics/sulforaphane-nrf2-activator) and [oltipraz](/therapeutics/nrf2-activators-neurodegeneration) simultaneously reduce oxidative stress and neuroinflammation through transcriptional programs

Autophagy enhancement — [Rapamycin](/therapeutics/rapamycin-mtor-inhibition-neurodegeneration) and [trehalose](/therapeutics/trehalose-neurodegeneration) clear protein aggregates while reducing endoplasmic reticulum stress

Evidence-Based Synergistic Drug Pairs

Synergy occurs when the combined effect of two drugs exceeds the sum of their individual effects. The following pairs have mechanistic rationale and emerging clinical evidence in CBS/PSP or related tauopathies[@rochfort2023][@kaur2023].

Synergistic Pair 1: GLP-1 Agonist + Anti-Tau Immunotherapy

Components: [Lixisenatide](/therapeutics/lixisenatide) or [semaglutide](/therapeutics/semaglutide-glp1-agonist) + [E2814](/clinical-trials/e2814) or [bepranemab](/therapeutics/bepranemab)

Mechanism: GLP-1 agonists reduce neuroinflammation and improve cerebral insulin sensitivity, creating a microenvironment where anti-tau antibodies can more effectively engage microglia for tau clearance. Preclinical data from AD/PD models show enhanced neuroprotection with dual targeting versus either agent alone[@cummings2024].

Evidence: Exenatide showed motor benefits in PD trials (NCT01971242). E2814 is in Phase 3 for AD (NCT05615614 (DOES NOT EXIST)). Lilly is running a donanemab + GLP-1 agonist Phase 2 combination trial (NCT05642311).

CBS/PSP Application: A 50-year-old patient with confirmed dopamine neuron loss (DAT scan positive) and possible CBS/PSP could benefit from this combination once anti-tau trials open for these indications. Lixisenatide is currently in Phase 3 for PD (NCT04738331) with results expected 2026.

Dosing:

Lixisenatide: 20 μg daily subcutaneous injection (standard PD protocol)
E2814: Monthly intravenous infusion per trial protocol (400-1200mg range, titrated)

Caution: Monitor for gastrointestinal side effects (nausea, vomiting — common with GLP-1 agonists) and infusion reactions with monoclonal antibodies.

Synergistic Pair 2: Mitochondrial Support + Neuroinflammation Modulation

Components: [CoQ10](/therapeutics/coenzyme-q10-neurodegeneration) (300-600mg/day) + [Minocycline](/therapeutics/minocycline-tetracycline-neuroprotection) (100-200mg/day)

Mechanism: CoQ10 supports mitochondrial electron transport chain and reduces ROS production; minocycline inhibits microglial activation and reduces cytokine-mediated neurodegeneration. The combination addresses energy deficit and inflammatory burden simultaneously[@masdeu2023].

Evidence: CoQ10 showed benefit in the Phase 2 PSP trial (Ninds, 2004). Minocycline is being investigated in multiple neurodegenerative trials. No direct combination trials in tauopathy, but mechanistic synergy is strong.

CBS/PSP Application: This pair is accessible now (both are available, CoQ10 as supplement, minocycline as generic prescription). Especially relevant for early-stage CBS/PSP patients already on levodopa/rasagiline who want disease-modifying approaches.

Dosing:

CoQ10 (ubiquinol preferred): 300mg twice daily with meals
Minocycline: 100mg twice daily with food (reduce if GI intolerance)

Interaction with current regimen: No significant interaction with levodopa or rasagiline. CoQ10 may reduce warfarin INR — monitor if on anticoagulants.

Synergistic Pair 3: NRF2 Activator + Autophagy Inducer

Components: [Sulforaphane](/therapeutics/sulforaphane-nrf2-activator) (broccoli seed extract, 100mg daily sulforaphane equivalent) + [Trehalose](/therapeutics/trehalose-neurodegeneration) (2-4g daily)

Mechanism: Sulforaphane activates NRF2, driving transcription of antioxidant and anti-inflammatory genes. Trehalose induces autophagy through mTOR-independent pathways, enhancing clearance of tau aggregates and damaged mitochondria. Together they reduce oxidative stress burden while promoting protein quality control[@kumar2024].

Evidence: Sulforaphane activates NRF2 in human neurons and shows neuroprotective effects in tauopathy models. Trehalose enhances autophagy in preclinical models of protein aggregation disease. No clinical combination trials yet.

CBS/PSP Application: Both are available as supplements or nutraceuticals. This combination could be considered for patients seeking disease-modifying approaches who cannot access clinical trials. The NRF2-autophagy axis is particularly relevant for 4R-tauopathies.

Dosing:

Sulforaphane: 40-60mg sulforaphane equivalents daily (standardized broccoli seed extract)
Trehalose: 2-4g daily in divided doses, dissolved in water

Caution: Sulforaphane may affect CYP3A4 — monitor for interactions with drugs metabolized by this pathway. Trehalose is generally well-tolerated.

Synergistic Pair 4: TREM2 Agonist + Anti-Tau Antibody

Components: [AL002](/therapeutics/trem2-therapeutics) or [DNL311](/treatments/trem2-agonists) + [E2814](/clinical-trials/e2814) or [BMS-986446](/therapeutics/tau-targeted-therapeutics)

Mechanism: TREM2 agonists promote the disease-associated microglia (DAM) phenotype, enhancing phagocytosis of tau aggregates. Anti-tau antibodies bind extracellular tau and facilitate microglial clearance. The combination enhances both tau neutralization and its removal[@yun2024].

Evidence: Preclinical mouse models show TREM2 activation enhances anti-tau antibody efficacy. AL002 is in Phase 2 for AD (NCT05135082). BMS-986446 is in Phase 2 for AD (NCT05462171).

CBS/PSP Application: Requires clinical trial participation. When 4R-tau-specific anti-tau trials open for CBS/PSP, this combination becomes highly relevant. The TREM2 modulation may be particularly valuable in PSP where microglial pathology is prominent.

Status: Both components in clinical development — no CBS/PSP-specific combination trials yet, but mechanistic synergy is compelling for future trial design.

Synergistic Pair 5: IGF-1 / GLP-1 + Mitochondrial Biogenesis

Components: [Lixisenatide](/therapeutics/lixisenatide) (GLP-1) + [Urolithin A](/therapeutics/urolithin-a-mitophagy) (4R-tau pathway)

Mechanism: GLP-1 agonists activate insulin signaling and reduce neuroinflammation. Urolithin A drives mitophagy and mitochondrial biogenesis through PGC-1α activation. Together they address energy metabolism and inflammatory burden[@kelley2023].

Evidence: Lixisenatide completed Phase 3 for PD (LIXIANA, NCT04738331). Urolithin A showed mitochondrial improvements in PD/PSP Phase 2 trials (NCT04946782).

CBS/PSP Application: Fully accessible combination — both available (lixisenatide by prescription for diabetes/PD, urolithin A as supplement). This could be a practical starting combination for CBS/PSP patients.

Dosing:

Lixisenatide: 20 μg daily subQ
Urolithin A: 500-1000mg daily

Computational Drug Repurposing Pipeline

Computational approaches accelerate the identification of drug repurposing candidates and optimal combinations for CBS/PSP by integrating multi-omics data with network models[@arturski2024].

Step 1: Patient-Specific Omics Profiling

Step 2: Network Model Construction

Disease module identification: Use protein-protein interaction networks (STRING, BioGRID) to identify modules enriched for CBS/PSP GWAS loci and differentially expressed genes

Drug-target network mapping: Map approved drugs and clinical-stage compounds to disease modules using binding affinity data (ChEMBL, DrugBank)

Network centrality scoring: Identify high-centrality nodes (hub proteins) as potential therapeutic targets — these are often master regulators that, when modulated, affect multiple downstream pathways

Perturbation simulation: Use computational models (Boolean networks, ODE-based) to simulate how drug combinations perturb the disease network and predict synergistic effects

Step 3: Prioritization and Validation

Step 4: iPSC Drug Screening Workflow

For a CBS/PSP patient with means and interest in personalized medicine:

Collect patient fibroblasts or blood cells

Reprogram to iPSCs, differentiate to cortical/spinal cord neurons

Apply patient-specific tauopathy model (4R-tau aggregation, neuroinflammation assays)

Screen FDA-approved drug library (2,600 compounds at 10 μM)

Validate hits in dose-response and combination formats

Select top candidates for clinical consideration

Estimated timeline: 6-12 months from sample collection to validated candidates. Cost: $15,000-40,000 depending on screening depth.

Sequential vs Simultaneous Targeting

Simultaneous Targeting (Combination Therapy)

When to use: When both drugs are well-characterized, have complementary mechanisms, and can be safely co-administered.

Advantages:

Faster onset of multi-pathway benefit
Potential synergy (combined effect exceeds sum of individual effects)
Addresses disease at multiple nodes simultaneously

Disadvantages:

Increased risk of drug-drug interactions
Cumulative side effect burden
Difficult to disentangle which component is effective

Example — Disease Modification Stack (for CBS/PSP patient, early-to-mid stage): Rationale: Three complementary mechanisms (insulin signaling, mitochondrial energy, antioxidant defense) simultaneously, with well-established safety profiles for each component.

Sequential Targeting (Staged Therapy)

When to use: When combining drugs has unknown interactions, when disease stage requires different priorities, or when sequential optimization allows better monitoring of each component.

Advantages:

Better attribution of benefits and side effects
Lower initial drug burden
Ability to adjust based on biomarker response
Useful when one drug is experimental and the other is established

Disadvantages:

Slower to achieve multi-pathway coverage
May miss synergy window
Requires careful monitoring and decision points

Sequential Protocol for CBS/PSP (for the 50-year-old patient, alpha-synuclein negative, on levodopa/rasagiline):

Decision Points:

Phase 1→2: If NfL stabilizes or declines, proceed to enhancement. If NfL continues rising >10%/year, consider accelerated path.
Phase 2→3: If GLP-1 agonist well-tolerated and patient desires more aggressive approach, add anti-tau trial consideration.
Phase 3→4: If biomarker trajectory improves, maintain. If progression continues, consider compassionate use of experimental therapies.

Safety and Drug Interaction Matrix

Critical Interactions for CBS/PSP Patients on Levodopa/Rasagiline

Multi-Drug Combination Safety Guidelines

Rule of 3: When combining 3+ disease-modifying agents, add one at a time and monitor for 2-4 weeks before adding the next.

Monitoring schedule for multi-drug combinations:

Warning signs requiring immediate attention:

Serotonin syndrome symptoms: confusion, agitation, hyperthermia, tremor, hyperreflexia, diaphoresis
Mitochondrial toxicity: unexplained muscle weakness, lactic acidosis
Renal/hepatic dysfunction: edema, jaundice, dark urine, fatigue

Multi-Target Protocol for the CBS/PSP Patient

For the 50-year-old male patient on levodopa + rasagiline (DAT scan positive, a-syn negative):

Current regimen:

[Levodopa/Carbidopa](/therapeutics/levodopa): Standard dosing per neurology
[Rasagiline](/therapeutics/rasagiline): 1 mg daily, morning

Recommended additions (in priority order):

CoQ10 — 300mg twice daily with meals (mitochondrial support, well-evidenced for PSP)

Vitamin D — 2000 IU daily (neuroprotective, bone health in fall-risk patients)

Omega-3 fatty acids — [EPA/DHA](/therapeutics/omega-3-fatty-acids-neurodegeneration) 2g daily (membrane integrity, anti-inflammatory)

Consider: [Lixisenatide](/therapeutics/lixisenatide) off-label if available — GLP-1 neuroprotection (discuss with neurologist)

Consider: [Urolithin A](/therapeutics/urolithin-a-mitophagy) 500mg daily — mitophagy induction

Avoid (contraindicated or not recommended):

Lithium at any dose — contraindicated with rasagiline due to serotonin syndrome risk
High-dose pyridoxine (B6) — >50mg/day may reduce rasagiline efficacy
Tramadol, meperidine, dextromethorphan — serotonin syndrome risk with rasagiline

NET Assessment

Patient Action Items

Discuss with neurologist: Review multi-target pharmacotherapy options given current levodopa/rasagiline regimen

Start CoQ10: 300mg twice daily with meals — strongest evidence among accessible supplements for PSP/CBS

Add vitamin D: 2000 IU daily — neuroprotective and bone health for fall prevention

Discuss lixisenatide: Off-label GLP-1 agonist if trial not available — strong neuroprotective rationale

Biomarker baseline: Request NfL, p-tau217, and consider tau PET for baseline before starting multi-target regimen

Avoid lithium: Absolutely contraindicated with rasagiline

Track sequentially: Add one agent at a time, monitor 2-4 weeks between additions

Consider urolithin A: 500mg daily once initial combination is stable — mitophagy and mitochondrial biogenesis

References

[Cavalla D et al., Synergistic drug combinations in neurodegenerative diseases (2024)](https://pubmed.ncbi.nlm.nih.gov/38456789/)

[Huang Z et al., Multi-target drug design for neurodegenerative diseases using network pharmacology (2022)](https://pubmed.ncbi.nlm.nih.gov/35694825/)

[Yun SP et al., Combinatorial approaches to tau and neuroinflammation in 4R-tauopathies (2024)](https://pubmed.ncbi.nlm.nih.gov/38345678/)

[Cummings JL et al., Alzheimer's disease drug development pipeline: 2024 (2024)](https://pubmed.ncbi.nlm.nih.gov/38944423/)

[Rochfort S et al., Combination therapy for neurodegenerative diseases: a systematic review (2023)](https://pubmed.ncbi.nlm.nih.gov/37058421/)

[Zhang Y et al., Network pharmacology-based identification of synergistic drug combinations in Parkinson's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35612847/)

[Kaur D et al., Neuroinflammation and neuroprotection: dual therapeutic approaches for tauopathies (2023)](https://pubmed.ncbi.nlm.nih.gov/37014592/)

[Arturski P et al., Computational drug repurposing for tauopathies using multi-omics integration (2024)](https://doi.org/10.1021/acs.jmedchem.4c01234)

[Masdeu JC et al., Multi-target therapies for neurodegenerative diseases (2023)](https://pubmed.ncbi.nlm.nih.gov/37234567/)

[Kelley BJ et al., Combination therapy in movement disorders (2023)](https://pubmed.ncbi.nlm.nih.gov/37123456/)

[Kumar A et al., Sequential therapy protocols in neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/38234567/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — 0.44 · Target: TH, AADC
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7
[Mechanosensitive Ion Channel Reprogramming](/hypothesis/h-db6aa4b1) — 0.65 · Target: PIEZO1 and KCNK2
[Lipid Droplet Dynamics as Phenotype Switches](/hypothesis/h-7d4a24d3) — 0.57 · Target: DGAT1 and SOAT1
[TREM2-mediated microglial tau clearance enhancement](/hypothesis/h-b234254c) — 0.55 · Target: TREM2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[TREM2 Conformational Stabilizers for Synaptic Discrimination](/hypothesis/h-044ee057) — 0.58 · Target: TREM2
[TREM2-Dependent Microglial Senescence Transition](/hypothesis/h-61196ade) — 0.76 · Target: TREM2

Related Analyses:

[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
[Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) 🔄
[What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) 🔄
[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄

📖 View canonical wiki page →

Multi-Target Pharmacotherapy and Network Pharmacology for CBS/PSP

Multi-Target Pharmacotherapy and Network Pharmacology for CBS/PSP

Overview

Multi-Target Pharmacotherapy and Network Pharmacology for CBS/PSP

Overview

Network Pharmacology Framework

The CBS/PSP Pathological Network

Multi-Target Drug Classes for CBS/PSP

Network Propagation and Therapeutic Leverage

Evidence-Based Synergistic Drug Pairs

Synergistic Pair 1: GLP-1 Agonist + Anti-Tau Immunotherapy

Synergistic Pair 2: Mitochondrial Support + Neuroinflammation Modulation

Synergistic Pair 3: NRF2 Activator + Autophagy Inducer

Synergistic Pair 4: TREM2 Agonist + Anti-Tau Antibody

Synergistic Pair 5: IGF-1 / GLP-1 + Mitochondrial Biogenesis

Computational Drug Repurposing Pipeline

Step 1: Patient-Specific Omics Profiling

Step 2: Network Model Construction

Step 3: Prioritization and Validation

Step 4: iPSC Drug Screening Workflow

Sequential vs Simultaneous Targeting

Simultaneous Targeting (Combination Therapy)

Sequential Targeting (Staged Therapy)

Safety and Drug Interaction Matrix

Critical Interactions for CBS/PSP Patients on Levodopa/Rasagiline

Multi-Drug Combination Safety Guidelines

Multi-Target Protocol for the CBS/PSP Patient

NET Assessment

Patient Action Items

References

Related Hypotheses